Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial-Reference-Cited by-同舟云学术

Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial

Published:2023-12 Issue:6 Volume:8 Page:102036
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Brighi N.,Conteduca V.,Gurioli G.,Scarpi E.,Cursano M.C.,Bleve S.,Lolli C.,Schepisi G.,Casadei C.,Gianni C.,Ulivi P.,De Giorgi U.

Funder

Sanofi Genzyme

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference39 articles.

1. COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

2. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

3. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration- resistant prostate cancer progressing after docetaxel treatment: a randomised open- label trial;de Bono;Lancet,2010

4. ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer;Parker;N Engl J Med,2013

5. VISION Investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer;Sartor;N Engl J Med,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review;European Urology Oncology;2024-05

2. Unlocking the promise of liquid biopsies in precision oncology;The Journal of Liquid Biopsy;2024-03